A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants

StatusCompleted
PhasePhase 1
SponsorAbbVie
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 7 entries Show 4 more changesShow less
    • Trial completed
    • Primary and study completion dates changed from estimate of Sep 2026 to Sep 14, 2026
    • Eligibility criteria expanded, about 6 words
    • Site details revised
  2. Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised
    v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Feb 2026 to Sep 2026
    • Start date changed from estimate of Oct 14, 2025 to May 4, 2026
    • Study sites: 0 to 1
    v3
  4. Start date: May 12, 2025 to Oct 14, 2025
    • Primary and study completion dates: Sep 2025 to Feb 2026
    v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AbbVie
349 trials monitored
See 27 trials at risk
The main objective of this study is to assess the safety and tolerability of ABBV-932 in healthy adult male participants.
Trial Details
NCT Number NCT06953934
Lead Sponsor AbbVie
Conditions
(from sponsor)		 Healthy Volunteer
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov